Choosing a right surfactant for respiratory distress syndrome treatment

Neonatology

Volumn 95, Issue 1, 2008, Pages 1-5

  Ramanathan, Rangasamy ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Natural, modified surfactants; Respiratory distress syndrome treatment; Respiratory distress syndrome, right surfactant; Synthetic surfactants

Indexed keywords

BERACTANT; CALFACTANT; DIPALMITOYLPHOSPHATIDYLCHOLINE; LUCINACTANT; PHOSPHOLIPID; PLASMALOGEN; PORACTANT; SURFACTANT; SURFACTANT PROTEIN B; SURFACTANT PROTEIN C;

AIRWAY PRESSURE; ANTIINFLAMMATORY ACTIVITY; ARTIFICIAL VENTILATION; BODY WEIGHT; CHILD CARE; GESTATIONAL AGE; HEALTH CARE COST; HOSPITAL COST; HUMAN; INFANT MORTALITY; LARYNGEAL MASK; NEWBORN; NEWBORN MORTALITY; OUTCOME ASSESSMENT; POSITIVE END EXPIRATORY PRESSURE; PREMATURITY; PRIORITY JOURNAL; PROTEIN CONTENT; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; VISCOSITY;

BIOLOGICAL PRODUCTS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; PHOSPHOLIPIDS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN B; PULMONARY SURFACTANTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY DISTRESS SYNDROME, NEWBORN; RETROSPECTIVE STUDIES;

ANIMALIA;

EID: 52849114019     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000151749     Document Type: Review

References (36)

1. Slattery MM, Morrison JJ: Preterm delivery. Lancet 2002;360:1489-1497.
2. Callaghan WM, MacDorman MF, Rasmussen SA, Qin C, Lackritz EM: The contribution of preterm birth to infant mortality in the United States. Pediatrics 2006;118:1566-1573.
3. Lemons JA, Bauer CR, Oh W, Korones S, Papile LA, Stoll BJ, Verter J, Temprosa M, Wright LL, Ehrenkranz RA, Fanaroff AA, Stark A, Carlo W, Tyson JE, Donovan EF, Shankaran S, Stevenson DK: Very low birth weight infant outcomes of the NICHD Neonatal Research Network, January 1995-December 1996. Pediatrics 2001;107:e1-e8.
4. Horbar JD, Wright LL, Soll RF Wright EC, Fanaroff AA, Korones SB, Shankaran S, Oh W, Fletcher BD, Bauer CR: A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1993;123:757-766.
5. Alvarado M, Hingre R, Hakason D, Gross S: Clinical trial of Survanta versus Exosurf in infants <1,500 g with respiratory distress syndrome. Pediatr Res 1993;33:314A.
6. Pearlman SA, Leef KH, Stefano JL, Speer ML, Esterly KL: A randomized trial comparing Exosurf versus Survanta in the treatment of neonatal RDS. Pediatr Res 1993;33:340A.
7. Sehgal SS, Ewing CK, Richards T, Taeusch HW: Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study. J Natl Med Assoc 1994;86:46-52.
8. Vermont-Oxford Neonatal Network: A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics 1996;97:1-6.
9. Hudak ML, Farrell EE, Rosenberg AA, Jung Al, Auten Rl, Durand DJ, Horgan MJ, Buckwald S, Belcastro MR, Donohue PK, Carrion V, Maniscalco WW, Balsan MJ, Torres BA, Miller RR, Jansen RD, Graeber JE, Laskay KM, Matteson EJ, Egan EA, Brody AS, Martin DJ, Riddlesberger MM, Montgomery P: A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. J Pediatr 1996;128:396-406.
10. Hudak ML, Martin DJ, Egan EA, Matteson EJ, Cummings NJ, Jung AL, Kimberlin LV, Auten RL, Rosenberg AA, Asselin JM, Belcastro MR, Donohue PK, Hamm CR Jr, Jansen RD, Brody AS, Riddlesberger MM, Montgomery P: A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics 1997;100:39-50.
11. Modanlou HD, Beharry K, Padilla G, Norris K, Safvati S, Aranda JV: Comparative efficacy of Exosurf and Survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity. J Perinatol 1997;17:455-460.
12. Da Costa DE, Pai MG, Al Khusaiby SM: Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: experiences in a developing country. Pediatr Pulmonol 1999;27:312-317.
13. Rollins M, Jenkins J, Tubman R, Corkey C, Wilson D: Comparison of clinical responses to natural and synthetic surfactants. J Perinat Med 1993;21:341-347.
14. Kukkonen AK, Virtanen M, Jarvenpaa AL, Pokela ML, Ikonen S, Fellman V: Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant? Acta Paediatr 2000;89:556-561.
15. Ainsworth SB, Beresford MW, Milligan DW, Shawn NJ, Matthews JN, Fenton AC, Ward Platt MP: Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: a randomised trial. Lancet 2000;355:1387-1392.
16. Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A, Kornacka MK, Merritt TA, Segal R, Schaber CJ, Tsai H, Massaro J, d'Agostino R, International Surfaxin Collaborative Study Group: A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics 2005;115:1018-1029.
17. Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, Wiswell TE, Gadzinowski J, Hajdu J, Bernstein G, Sanchez-Luna M, Segal R, Schaber CJ, Massaro J, d'Agostino R, Surfaxin Therapy Against Respiratory Distress Syndrome Collaborative Group: A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 2005;115:1030-1038.
18. Kattwinkel J: Synthetic surfactants: the search goes on. Pediatrics 2005;115:1075-1076.
19. Engle WA and the Committee on Fetus and Newborn: Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics 2008;121:419-432.
20. Tonks A, Parton J, Tonks AJ, Morris RHK, Finall A, Jones KP, Jackson SK: Surfactant phospholipid DPPC downregulates monocyte respiratory burst via modulation of PKC. Am J Physiol 2005;288:L1070-L1080.
21. Notter RH, Wang Z, Egan EA, Holm BA: Component specific surface and physiological activity in bovine-derived surfactants. Chem Phys Lipids 2002;114:21-34.
22. Walther FJ, Hernandez-Juviel J, Bruni R, Waring AJ: Spiking Survanta with synthetic surfactant peptides improves oxygenation in surfactant deficient mice. Am J Physiol 1997;156:855-861.
23. Rudiger M, von Baehr A, Haupt R, Wauer RR, Rustow B: Preterm infants with high polyunsaturated fatty acid and plasmalogen content in tracheal aspirates develop bronchopulmonary dysplasia less often. Crit Care Med 2000;28:1572-1577.
24. Bloom BT, Kattwinkel J, Hall RT, Delmore PM, Egan EA, Trout JR, Malloy MH, Brown DR, Holzman IR, Coghill CH, Carlo WA, Pramanik AK, McCaffree MA, Toubas PL, Laudert S, Gratny LL, Weatherstone KB, Seguin JH, Willett LD, Gutcher GR, Mueller DH, Topper WH: Comparison of Infasurf (calf lung surfactant extract) to Survanta (beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics 1997;100:31-38.
25. Bloom BT, Clark RH: Comparison of Infasurf (calfactant) and Survanta (beractant) in the prevention and treatment of respiratory distress syndrome. Pediatrics 2005;116:392-399.
26. Speer CP, Gefeller O, Groneck P, Laufkötter E, Roll C, Hanssler L, Harms K, Herting E, Boenisch H, Windeler J: Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child 1995;72:F8-F13.
27. Baroutis G, Kaleyias J, Liarou T, Papathoma E, Hatzistamatiou Z, Costalos C: Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Eur J Pediatr 2003;162:476-480.
28. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K, North American Study Group: A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 2004;21:109-119.
29. Halliday HL: History of surfactant from 1980. Biol Neonate 2005;87:317-322.
30. Malloy CA, Nicoski P, Muraskas JK: A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr 2005;94:779-784.
31. Gerdes JS, Seiberlich W, Sivieri EM, Marsh W, Varner DL, Turck CJ, York JM: An open-label comparison of calfactant and poractant alfa administration traits and impact on neonatal intensive care unit resources. J Pediatr Pharmacol Ther 2006;11:92-100.
32. Marsh W, Smeeding J, York JM, Ramanathan R, Sekar K: A cost minimization comparison of two surfactants - beractant and poractant alfa - based upon prospectively designed, comparative clinical trials. J Pediatr Pharmacol Ther 2004;9:117-125.
33. Ramanathan R: Optimal ventilatory strategies and surfactant to protect the preterm lings. Neonatology 2008;93:302-308.
34. Clark RH, Auten RL, Peabody J: A comparison of the outcomes of neonates treated with two different natural surfactants. J Pediatr 2001;139:828-831.
35. Ramanathan R, Saunders WB, Lavin PT, Sekar KC, Ernst FR, Bhatia J: Mortality differences among preterm neonates treated with three different natural surfactants: analyses from a large national database. Acta Pediatr 2007;96(suppl 456):107.
36. Sekar KC, Bhatia J, Ernst FR, Saunders WB, Lavin PT, Ramanathan R: Resource use in preterm neonates with respiratory distress syndrome treated with one of three different natural surfactants: analyses using a large hospital discharge database. Acta Pediatr 2007;96(suppl 456):109.